Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, we wish to inform you that the Board of Directors ....
Awaiting price reaction for this filing.
The Board of Directors of MPS Pharmaa Limited (formerly Advik Laboratories Limited), at its meeting held on March 3, 2026, approved the retrenchment of 10 permanent factory workers at its manufacturing facility in Roz-Ka-Meo Industrial Area, Sohna, Haryana, effective April 2, 2026. The move is part of workforce rationalization as the company plans to diversify into manufacturing Ayurvedic, Unani, and Homeopathic medicines, drugs, and Nutraceutical products, responding to growing consumer demand for natural healthcare solutions. The retrenchment is being carried out in compliance with the Industrial Relations Code, 2020, and all statutory dues and compensation are being paid to the affected workers. The company had earlier informed the stock exchange about this proposed diversification on September 2, 2025.
The company is restructuring its workforce to pivot toward Ayurvedic, Unani, Homeopathic, and Nutraceutical products. While short-term costs may rise due to retrenchment compensation, the shift could position the company in higher-growth healthcare segments. Shareholders should watch for updates on the new business line and its financial impact.